Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase® Grants Stock Options

GlobeNewswire November 21, 2022

Theralase Technologies (TSXV:TLT) closes private placement

John Ballem  November 18, 2022

Theralase ® Closes Private Placement Equity Financing

GlobeNewswire November 17, 2022

Theralase (TSXV:TLT) commences C$2.5M follow-on private placement equity financing

Azuka Onwuka October 3, 2022

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

GlobeNewswire October 3, 2022

Theralase® Announces Warrant Extension

GlobeNewswire September 29, 2022

Theralase (TSXV:TLT) closes $2.5M private placement

John Ballem  September 23, 2022

Theralase® Closes $2.5M Private Placement Equity Financing

GlobeNewswire September 22, 2022

Theralase Releases Q222 Interim Financial Statements

GlobeNewswire August 29, 2022

Theralase (TSXV:TLT) granted Brazilian patent

Trevor Abes  June 28, 2022

Theralase Expands Intellectual Property Portfolio

GlobeNewswire June 28, 2022

Theralase (TSXV:TLT) research - one of the most downloaded papers in Translational Biophotonics

Shoran Devi June 24, 2022

Theralase® Research - One of the Top 10 Most Downloaded Papers

GlobeNewswire June 24, 2022

Theralase (TSXV:TLT) announces publication of its Phase Ib NMIBC clinical study

John Ballem  June 21, 2022

Theralase® Phase Ib NMIBC Clinical Study Published

GlobeNewswire June 21, 2022

Theralase Releases Q122 Interim Financial Statements

GlobeNewswire May 30, 2022

Theralase Release FY2021 Audited Financial Statements

GlobeNewswire April 29, 2022

Theralase (TSXV:TLT) bladder cancer clinical study shows encouraging responses

Caroline Egan  April 5, 2022

Theralase® Provides Update on Phase II Bladder Cancer Clinical Study

GlobeNewswire April 5, 2022

Today’s market summary: cannabis stocks lift sentiment as blockade enters second week

Trevor Abes  February 9, 2022